Recombinant human decorin upregulates p57KIP2 expression in HepG2 hepatoma cell lines

Hamid,Abdu Selim; Li,Jinran; Wang,Yali; Wu,Xiaodong; Ali,Hassan  Abdellah Ahmed; Du,Zhenwu; Bo,Lihua; Zhang,Yucheng; Zhang,Guizhen

doi:10.3892/mmr.2013.1510

Recombinant human decorin upregulates p57KIP2 expression in HepG2 hepatoma cell lines

Authors:
- Abdu Selim Hamid
- Jinran Li
- Yali Wang
- Xiaodong Wu
- Hassan Abdellah Ahmed Ali
- Zhenwu Du
- Lihua Bo
- Yucheng Zhang
- Guizhen Zhang
View Affiliations

Affiliations: Central Laboratory, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Clinical Medicine of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: June 6, 2013 https://doi.org/10.3892/mmr.2013.1510
Pages: 511-516

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing the expression of cyclin-cyclin-dependent kinase inhibitors (cyclin-CDK) using small molecule inhibitors is a therapeutic strategy used to suppress cancer cell growth. Decorin (DCN), a functional component of the extracellular matrix, has been implicated in the suppression of cell proliferation by upregulating p21, a cyclin-CDK inhibitor. The purpose of this study was to examine the effect of recombinant decorin on the reactivation of p57KIP2, whose expression is silenced in hepatocellular carcinoma (HCC). Cell viability assay, cell cycle analysis, apoptosis assay and quantitative real time-PCR experiments were performed in three groups of HepG2 human cells: Uninfected HepG2 cells (control group), pcDNA3.1 vector-infected HepG2 cells (pcDNA3.1 group) and pcDNA3.1-DCN-infected HepG2 cells (pcDNA3.1‑DCN group). Our results revealed that recombinant human decorin inhibited cell proliferation, induced G0/G1 phase arrest and induced apoptosis by increasing the expression of caspase-3 in the pcDNA3.1-DCN group. The expression of p57KIP2 mRNA in the pcDNA3.1-DCN group was higher than in the pcDNA3.1 and control groups (P<0.05); however, there was no statistically significant difference between the control and pcDNA3.1 groups (P>0.05). In conclusion, recombinant human decorin reactivated p57KIP2 expression in HepG2 cells. As the expression level of p57KIP2 is downregulated in HCC, our finding may serve as a basis for the therapy and prognosis of HCC, although further studies are required.

View Figures

View References

1	Colak D, Chishti MA, Al-Bakheet AB, et al: Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer. 9:1462010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
3	El-Serag HB, Davila JA, Petersen NJ and McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
4	Zhang MF, Zhang ZY, Fu J, Yang YF and Yun JP: Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med. 7:1102009. View Article : Google Scholar
5	Jain S, Singhal S, Lee P and Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2:105–118. 2010.
6	McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 19:3–23. 2005. View Article : Google Scholar : PubMed/NCBI
7	Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
8	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
9	Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491. 2009. View Article : Google Scholar : PubMed/NCBI
10	Nguyen MH, Whittemore AS, Garcia RT, et al: Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2:820–824. 2004. View Article : Google Scholar : PubMed/NCBI
11	Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 67:609–652. 1998. View Article : Google Scholar : PubMed/NCBI
12	Iozzo RV, Moscatello DK, McQuillan DJ and Eichstetter I: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 274:4489–4492. 1999. View Article : Google Scholar : PubMed/NCBI
13	Reed CC and Iozzo RV: The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 19:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
14	Baghy K, Dezso K, László V, et al: Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest. 91:439–451. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gu Y, Zhang S, Wu Q, et al: Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J Exp Clin Cancer Res. 29:62010. View Article : Google Scholar : PubMed/NCBI
16	Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ and Iozzo RV: Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest. 101:406–412. 1998. View Article : Google Scholar : PubMed/NCBI
17	Csordás G, Santra M, Reed CC, et al: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem. 275:32879–32887. 2000.PubMed/NCBI
18	Bi X, Tong C, Dockendorff A, et al: Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 29:1435–1440. 2008. View Article : Google Scholar
19	Besson A, Dowdy SF and Roberts JM: CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kavanagh E and Joseph B: The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 1816:50–56. 2011.PubMed/NCBI
21	Pateras IS, Apostolopoulou K, Koutsami M, et al: Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer. 119:2546–2556. 2006. View Article : Google Scholar : PubMed/NCBI
22	Oya M and Schulz WA: Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer. 83:626–631. 2000. View Article : Google Scholar : PubMed/NCBI
23	Li JQ, Wu F, Usuki H, et al: Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol. 23:1537–1543. 2003.PubMed/NCBI
24	Larson PS, Schlechter BL, King CL, et al: CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer. 8:682008. View Article : Google Scholar : PubMed/NCBI
25	Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M and Matsuura N: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology. 61:221–225. 2001. View Article : Google Scholar : PubMed/NCBI
26	Atasoy P, Yilmaz E, Bozdogan O, Ayva S and Batislam E: Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a). Int Urol Nephrol. 41:55–60. 2009. View Article : Google Scholar
27	Guo H, Lv Y, Tian T, et al: Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis. 32:1897–1904. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Wang Y, Du Z, et al: Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther. 5:143–152. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hu Y, Sun H, Owens RT, et al: Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia. 11:1042–1053. 2009.PubMed/NCBI
30	De Luca A, Santra M, Baldi A, Giordano A and Iozzo RV: Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem. 271:18961–18965. 1996.PubMed/NCBI
31	Seidler DG, Goldoni S, Agnew C, et al: Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem. 281:26408–26418. 2006. View Article : Google Scholar : PubMed/NCBI
32	Lakhani SA, Masud A, Kuida K, et al: Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 311:847–851. 2006. View Article : Google Scholar : PubMed/NCBI
33	Ma Y and Cress WD: Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity. Oncogene. 26:3532–3540. 2007. View Article : Google Scholar : PubMed/NCBI
34	Scandura JM, Boccuni P, Massagué J and Nimer SD: Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA. 101:15231–15236. 2004. View Article : Google Scholar : PubMed/NCBI
35	Nan KJ, Guo H, Ruan ZP, Jing Z and Liu SX: Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol. 11:1237–1240. 2005. View Article : Google Scholar : PubMed/NCBI
36	Biaoxue R, Xiguang C, Hua L, et al: Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers. 26:9–21. 2011. View Article : Google Scholar : PubMed/NCBI
37	Shen L, Toyota M, Kondo Y, et al: Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 101:4131–4136. 2003. View Article : Google Scholar : PubMed/NCBI
38	Nakai S, Masaki T, Shiratori Y, et al: Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol. 20:769–775. 2002.PubMed/NCBI
39	Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res. 22:3191–3196. 2002.PubMed/NCBI